What are the various oral and intravenous iron supplement formulations and their typical dosages?

Types of Iron Supplements

Oral Iron Formulations

Ferrous sulfate remains the gold standard for oral iron therapy and should be the first-line oral formulation prescribed for most patients with iron deficiency. 1, 2

Available Oral Formulations

• Ferrous salts (ferrous sulfate, ferrous gluconate, ferrous fumarate) are the most commonly used and best-absorbed oral iron preparations 1, 3
• Ferric complexes with polysaccharides or succinylated milk proteins offer alternative options 3
• Ferric maltol, a lipophilic iron donor, represents a newer formulation 3
• Sucrosomial® iron (nanoparticle-encapsulated) is another recent development 3

Optimal Oral Dosing Strategy

Administer oral iron as ferrous salts in the morning on an empty stomach with approximately 100 mg of vitamin C or a glass of citrus juice to maximize absorption. 2

• The target daily intake is up to 200 mg elemental iron for 3-12 weeks to correct anemia and replenish stores 1
• Alternate-day dosing may improve fractional absorption and reduce gastrointestinal side effects 2
• Patients should remain upright for 30-60 minutes after dosing to prevent pill esophagitis 2

Factors That Impair Oral Iron Absorption

• Avoid afternoon dosing, which reduces absorption compared to morning administration 2
• Do not co-administer with food (especially cereals and grains), milk, tea, or coffee 2
• Calcium supplements, antacids, H2 inhibitors, and proton pump inhibitors markedly reduce iron absorption 2

Limitations of Oral Iron

• Only a small fraction of oral iron is absorbed, leading to accumulation in the intestinal lumen that causes constipation and gastrointestinal side effects 1
• These adverse effects reduce patient compliance 3

---

Intravenous Iron Formulations

For patients intolerant or refractory to oral iron, or requiring rapid correction, intravenous iron is the preferred treatment. 1, 4

High-Dose Single-Infusion Formulations

Ferric Carboxymaltose (FCM)

• Delivers 500-1000 mg elemental iron in a single 15-30 minute infusion 5, 1, 4
• In the United States, supplied in 750 mg vials; FDA labeling requires two doses one week apart (minimum 1500 mg total) 5
• Outside the United States, a single 1000 mg infusion is routine practice 5
• Dilute in 100 mL normal saline and infuse over 20-30 minutes 5

Critical Safety Concern: Clinically significant hypophosphatemia develops in 47-75% of FCM patients versus <10% with other IV iron formulations. 5 This represents a hyperphosphaturic hypophosphatemia mediated by elevated fibroblast growth factor-23 (FGF23). 5, 4

• Avoid FCM in patients requiring repeat infusions due to cumulative risk of hypophosphatemic osteomalacia, pseudofractures, and low-trauma fractures 5
• High-risk populations include those with recurrent blood loss, malabsorptive disorders, normal renal function, severe iron deficiency, low body weight, and low baseline phosphate 5
• Serum phosphate monitoring is mandatory for high-risk patients, those on long-term therapy, or receiving multiple high-dose infusions 5
• Severe hypophosphatemia may persist up to 6 months after a single infusion 5

Clinical Advantages:

• First IV iron formulation shown to reduce cardiovascular events and hospitalizations in congestive heart failure patients 5
• Hemoglobin response rate of 99.4% 5
• Single-dose convenience eliminates multiple clinic visits 5

Ferric Derisomaltose (Iron Derisomaltose/Iron Isomaltoside 1000)

• Provides single-dose convenience similar to FCM but with only 4% hypophosphatemia rate, making it preferable when repeat dosing may be needed 5, 4
• Can deliver 500-1000 mg in a single infusion 4
• In a 2025 randomized trial of pregnant women with moderate iron deficiency anemia, single-dose IV ferric derisomaltose achieved a 25% higher rate of non-anemic state without rescue therapy compared to oral iron 6

Multiple-Dose Formulations

Iron Sucrose

• Maximum 200 mg per administration, requiring 5-11 separate infusions to achieve full repletion 5
• Each 200 mg dose requires approximately 1 hour of infusion time 5
• Hypophosphatemia incidence is only 1%, making it suitable for repeated dosing 5
• Hemoglobin response rate of 98.3% 5
• The 2024 American Society of Hematology expert consensus states iron sucrose is "suboptimal" for ambulatory patients because total-dose infusions like FCM eliminate unnecessary multiple visits and reduce extravasation and infusion-reaction risk 5

Ferric Gluconate

For hemodialysis patients, administer 8 weekly doses of 125 mg elemental iron (total 1000 mg) as the standard repletion regimen. 7

• Alternative lower-dose regimen: 8 weekly doses of 62.5 mg (total 500 mg) 7
• Each dose must be given no more frequently than every other day to minimize infusion reactions 7
• Doses >125 mg per administration are not recommended due to higher incidence and severity of adverse events (hypotension, nausea, infusion reactions) 7
• May be delivered as slow IV injection at up to 12.5 mg/min (≈10 minutes for 125 mg dose) 7
• For iron deficits exceeding 1000 mg, extend to 10 weekly doses of 125 mg 7

Other IV Formulations

• Ferrumoxytol and sodium ferric gluconate are additional options that can be infused at varying doses 4
• Low-molecular-weight iron dextran has <10% hypophosphatemia incidence 5

---

Safety Considerations for All IV Iron Formulations

Infusion Reactions

• Anaphylaxis is extremely rare, occurring in <1 per 200,000 infusions 5
• Minor infusion reactions occur in 1-3% of patients across all modern formulations 5
• Most reactions are complement activation-related pseudo-allergies (CARPA) rather than true IgE-mediated allergic reactions 5
• Do not use test doses—they do not predict reactions and create false safety reassurance 5
• Routine pre-medication is not recommended for patients without prior IV iron reactions 5
• A 30-minute post-infusion observation period is not required for standard administrations 5

Management of Mild Infusion Reactions

If a mild reaction occurs, pause the infusion, wait 15 minutes, then restart at a slower rate; avoid diphenhydramine because its side effects can mimic worsening reactions. 5

Infection Risk

• A 2021 meta-analysis of 64 RCTs (19,322 participants) found IV iron increased infection risk by 16% versus oral iron or no iron (RR 1.16; 95% CI 1.03-1.29), representing 16 additional infections per 1,000 patients 5
• In inflammatory bowel disease patients, infection risk rose 73% (RR 1.73; 95% CI 1.11-2.71) 5
• Defer IV iron when active infection or sepsis is present unless anemia is immediately life-threatening 5
• No differential infection risk exists between IV iron formulations 5

Administration Requirements

• All IV iron must be administered in medical facilities by healthcare providers trained to manage hypersensitivity reactions 1

---

Post-Infusion Monitoring

• Check complete blood count and iron studies 4-8 weeks after the final infusion; avoid iron studies within the first 4 weeks because circulating iron interferes with assays 5
• Expected hemoglobin rise: 1-2 g/dL within 4-8 weeks 5
• Target ferritin: ≥50 ng/mL in the absence of inflammation 5
• Target transferrin saturation (TSAT): ≥20% 5
• For FCM specifically, measure serum phosphate in high-risk patients 5, 1

---

Clinical Indications for IV Iron (All Formulations)

• Chronic kidney disease (dialysis- and non-dialysis-dependent) 5
• Pregnancy-related iron-deficiency anemia 5, 6
• Heavy uterine bleeding 5
• Inflammatory bowel disease 5
• Congestive heart failure with iron deficiency 5
• Intolerance or unresponsiveness to oral iron 1, 4
• Need for rapid correction of anemia (e.g., prior to surgery) 1, 4

---

Practical Algorithm for Formulation Selection

For oral therapy: Start with ferrous sulfate dosed in the morning on an empty stomach with vitamin C or citrus juice; consider alternate-day dosing if gastrointestinal side effects occur. 1, 2

For IV therapy requiring single-dose convenience:

• If first-time IV iron or repeat dosing unlikely: Ferric carboxymaltose (1000 mg single dose) 5
• If repeat infusions anticipated or high hypophosphatemia risk: Ferric derisomaltose (lower hypophosphatemia rate of 4%) 5

For IV therapy in patients accepting multiple visits:

• Iron sucrose (200 mg per visit, 5-11 visits total) 5

For hemodialysis patients:

• Ferric gluconate (125 mg weekly × 8 doses) 7

Common pitfall: Prescribing FCM for patients with ongoing blood loss or malabsorptive disorders who will require repeat dosing—this creates cumulative hypophosphatemia risk and potential osteomalacia. 5